

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY .....	1
SCOPE OF REPORT .....	2
INTENDED AUDIENCE.....	3
INFORMATION SOURCES.....	4
ANALYST CREDENTIALS.....	4
RELATED BCC REPORTS .....	4
BCC ONLINE SERVICES.....	5
DISCLAIMER .....	5
CHAPTER TWO: EXECUTIVE SUMMARY.....	6
<i>SUMMARY TABLE GLOBAL OPHTHALMIC FORECAST BY DISEASE</i> <i>CLASS, THROUGH 2014 (\$ MILLIONS)</i> .....	6
<i>SUMMARY FIGURE GLOBAL OPHTHALMIC FORECAST BY</i> <i>DISEASE CLASS, 2008-2014 (\$ MILLIONS)</i> .....	7
EXECUTIVE SUMMARY (CONTINUED).....	8
CHAPTER THREE: OVERVIEW .....	9
HISTORY AND CURRENT STATE OF OPHTHALMOLOGY	
DISEASE.....	9
ESTABLISHED DRUG CLASSES IN OPHTHALMOLOGY.....	10
EMERGING DRUG CLASSES.....	10
VEGF-Trap Eye .....	10
Combination Therapies .....	10
COMPETITION BETWEEN VEGF INHIBITORS IN WET AMD.....	11
<i>TABLE 1 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN:</i> <i>PREVIOUS AND EXPECTED</i> .....	11
<i>TABLE 1 (CONTINUED)</i> .....	12
Expected Outcome of CATT trial: Avastin v. Lucentis .....	12
GENETIC SPECIFICATIONS OF OPHTHALMIC DISEASE.....	13
<i>TABLE 2 SUMMARY OF KNOWN GENES INFLUENCING DISEASE</i> .....	13
<i>TABLE 2 (CONTINUED)</i> .....	14
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT .....	14
<i>TABLE 3 RECENTLY APPROVED DRUGS, 2009</i> .....	14
<i>TABLE 4 SUMMARY PIPELINE FORECAST, 2012-2014</i> .....	15
CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE	
ANALYSIS.....	16
INDUSTRY STRUCTURE .....	16
MARKET CONCENTRATION AND PRICE SENSITIVITY.....	16
<i>TABLE 5 COMPANY BY DISEASE CLASS, 2009 REVENUE (\$</i> <i>MILLIONS)</i> .....	17
COMPETITIVE FACTORS.....	18

<i>TABLE 6 LARGE REVENUE, BRANDED DRUG SALES COMING OFF PATENT, 2009</i> .....	18
MARKET TRENDS .....	18
Demographics Offer Tremendous Long-run Opportunity .....	18
<i>TABLE 7 REVENUE GROWTH OF OPHTHALMOLOGY AS COMPARED TO TOTAL PHARMACEUTICAL MARKET, 2005-2009 (% YEAR-OVER-YEAR REVENUE GROWTH)</i> .....	19
An Increasingly Challenging Global Reimbursement Environment.....	19
Sustained Drug Delivery Is the Future of Retinal Care .....	20
Payment Structures Are Ever More Important to Revenue Uptake and Peak Sales. ....	20
Fundamental Patient Need: Blindness or Impaired Vision Are Among the Most Debilitating Diseases .....	21
Combination Therapies Promise Improved Therapeutic Response .....	21
Expansion of Prescription Therapies to Rural Communities .....	21
<i>TABLE 8 NUMBER OF U.S. HOSPITALS PROVIDING OPHTHALMIC CARE</i> .....	22
<i>TABLE 9 NUMBER OF TRAINED, LICENSED, AND CERTIFIED OPHTHALMOLOGISTS</i> .....	22
<i>TABLE 10 MARKET REVENUE AND SHARE BY LEADING OPHTHALMIC PLAYERS, 2009 (\$ MILLIONS/%)</i> .....	23
<i>TABLE 11 MARKET ANALYSIS BY DISEASE, 2008 AND 2009 (\$ MILLIONS)</i> .....	23
<i>TABLE 12 LEADING OPHTHALMIC THERAPIES, TOTAL SEGMENT, 2009 (\$ MILLIONS/%)</i> .....	24
NOTABLE MERGERS, ACQUISITIONS AND TRANSACTIONS.....	24
Roche/Genentech .....	24
Alcon/Novartis .....	25
Transaction Summary .....	25
Proposed Terms of Purchase .....	25
Integration Challenges and Opportunities.....	26
Fovea/Sanofi-Aventis.....	26
Fovea/Sanofi-Aventis (Continued) .....	27
CHAPTER FIVE: MARKETS BY DISEASE .....	28
SUMMARY OF MARKET DYNAMICS .....	28
<i>TABLE 13 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, THROUGH 2014 (\$ MILLIONS)</i> .....	29
AMD.....	29
PATHOPHYSIOLOGY AND PATHOGENESIS.....	29
Pathophysiology and Pathogenesis (Continued) .....	30

TREATMENT AND MANAGEMENT.....	31
Wet AMD.....	31
Wet AMD (Continued) .....	32
Dry AMD .....	33
FORECAST EPIDEMIOLOGY.....	33
<i>TABLE 14 GLOBAL FORECAST EPIDEMIOLOGY: WET AMD, PREVALENCE, THROUGH 2014 .....</i>	<i>33</i>
<i>TABLE 15 WET AMD REVENUE, 2009 SUMMARY, 2008 AND 2009 (\$ MILLIONS).....</i>	<i>34</i>
<i>TABLE 16 WET AMD, FORECAST BY COMPANY, THROUGH 2014 (\$ MILLIONS).....</i>	<i>34</i>
<i>TABLE 17 WET AMD REVENUE, FORECAST BY DRUG, THROUGH 2014 (\$ MILLIONS).....</i>	<i>35</i>
<i>TABLE 18 GLOBAL FORECAST EPIDEMIOLOGY: DRY AMD, PREVALENCE, THROUGH 2014 .....</i>	<i>35</i>
GLAUCOMA .....	35
PATHOPHYSIOLOGY AND PATHOGENESIS.....	35
Pathophysiology and Pathogenesis (Continued) .....	36
TREATMENT AND MANAGEMENT.....	37
Xalatan.....	37
Cosopt.....	38
Travatan.....	39
Lumigan .....	39
Lumigan (Continued).....	40
Prostaglandins Analysis: First Line Treatment for Glaucoma .....	41
GLAUCOMA MANAGEMENT STRATEGIES.....	41
Combination Therapies in Glaucoma Management .....	41
FORECAST EPIDEMIOLOGY.....	42
<i>TABLE 19 GLOBAL FORECAST EPIDEMIOLOGY: GLAUCOMA, PREVALENCE, THROUGH 2014 .....</i>	<i>42</i>
<i>TABLE 20 GLAUCOMA REVENUE, 2009 SUMMARY (\$ MILLIONS).....</i>	<i>43</i>
<i>TABLE 21 GLAUCOMA, FORECAST BY COMPANY, THROUGH 2014 (\$ MILLIONS).....</i>	<i>43</i>
<i>TABLE 22 GLAUCOMA REVENUE, FORECAST BY DRUG, THROUGH 2014 (\$ MILLIONS).....</i>	<i>44</i>
DIABETIC RETINOPATHY .....	44
PATHOPHYSIOLOGY AND PATHOGENESIS.....	44
Pathophysiology and Pathogenesis (Continued) .....	45
<i>TABLE 23 SUCCESSIVE STAGES OF DIABETIC RETINOPATHY.....</i>	<i>46</i>
TREATMENT AND MANAGEMENT.....	46
Avastin .....	46
Arxxant .....	47
Iluvien .....	47

FORECAST EPIDEMIOLOGY.....	48
<i>TABLE 24 GLOBAL FORECAST EPIDEMIOLOGY: DIABETIC</i>	
<i>RETINOPATHY, PREVALENCE, THROUGH 2014.....</i>	<i>48</i>
DRY-EYE DISEASE .....	48
PATHOPHYSIOLOGY AND PATHOGENESIS.....	48
TREATMENT AND MANAGEMENT.....	49
Restasis .....	49
Hyalein.....	50
Regulatory Update for Dry-eye Disease .....	51
FORECAST EPIDEMIOLOGY.....	52
<i>TABLE 25 GLOBAL FORECAST EPIDEMIOLOGY: DRY-EYE</i>	
<i>DISEASE, PREVALENCE, THROUGH 2014.....</i>	<i>52</i>
<i>TABLE 26 DRY-EYE DISEASE REVENUE, 2009 SUMMARY (\$</i>	
<i>MILLIONS/%).....</i>	<i>53</i>
<i>TABLE 27 DRY-EYE DISEASE, FORECAST BY COMPANY, THROUGH</i>	
<i>2014 (\$ MILLIONS).....</i>	<i>53</i>
<i>TABLE 28 DRY-EYE DISEASE REVENUE, FORECAST BY DRUG,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>54</i>
ALLERGIC DISEASES .....	54
<i>TABLE 29 ALLERGIC DISEASE REVENUE, 2009 SUMMARY (\$</i>	
<i>MILLIONS/%).....</i>	<i>55</i>
<i>TABLE 30 ALLERGIC DISEASE, FORECAST BY COMPANY,</i>	
<i>THROUGH 2014 (\$ MILLIONS/%) .....</i>	<i>55</i>
<i>TABLE 31 ALLERGIC DISEASE REVENUE, FORECAST BY DRUG,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>56</i>
INFECTIOUS DISEASES.....	56
<i>TABLE 32 INFECTIOUS DISEASE REVENUE, 2009 SUMMARY (\$</i>	
<i>MILLIONS).....</i>	<i>57</i>
<i>TABLE 33 INFECTIOUS DISEASE, FORECAST BY COMPANY,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>57</i>
<i>TABLE 34 INFECTIOUS DISEASE REVENUE, FORECAST BY DRUG,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>58</i>
INFLAMMATORY DISEASE.....	58
<i>TABLE 35 INFLAMMATORY DISEASE REVENUE, 2009 SUMMARY (\$</i>	
<i>MILLIONS/%).....</i>	<i>59</i>
<i>TABLE 36 INFLAMMATORY DISEASE, FORECAST BY COMPANY,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>60</i>
<i>TABLE 37 INFLAMMATORY DISEASE REVENUE, FORECAST BY</i>	
<i>DRUG, THROUGH 2014 (\$ MILLIONS) .....</i>	<i>60</i>
COMBINATION INFECTIOUS AND INFLAMMATORY	
DISEASE.....	60
<i>TABLE 38 DUAL INFLAMMATORY AND INFECTIVE DISEASE</i>	
<i>REVENUE, 2009 SUMMARY (\$ MILLIONS).....</i>	<i>61</i>

<i>TABLE 39 DUAL INFLAMMATORY AND INFECTIVE DISEASE, FORECAST BY COMPANY, THROUGH 2014 (\$ MILLIONS)</i> .....	62
<i>TABLE 40 DUAL INFLAMMATORY AND INFECTIVE DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 (\$ MILLIONS)</i> .....	62
OTHER OPHTHALMIC PRESCRIPTION TREATMENTS .....	62
ADDITIONAL DISEASES .....	62
Uveitis .....	62
Scleritis (Noninfectious and Infectious).....	63
Usher Syndrome .....	64
Coat's Disease .....	64
Eales Disease .....	65
Corneal Abrasion .....	65
Fuchs' Endothelial Dystrophy.....	66
Hypertensive Retinopathy .....	66
Stargardt's Disease (Juvenile Macular Degeneration) .....	66
Thygeson's Superficial Punctate Keratopathy .....	67
CHAPTER SIX: MARKETS BY GEOGRAPHY .....	68
SUMMARY.....	68
METHODOLOGY.....	68
MARKET SIZING DEFINITIONS .....	69
UNITED STATES.....	69
<i>TABLE 41 FORECAST U.S. EPIDEMIOLOGY: WET AMD, THROUGH 2014</i> .....	70
<i>TABLE 42 FORECAST U.S. EPIDEMIOLOGY: DRY AMD, THROUGH 2014</i> .....	70
<i>TABLE 43 FORECAST U.S. EPIDEMIOLOGY: GLAUCOMA, THROUGH 2014</i> .....	70
<i>TABLE 44 FORECAST U.S. EPIDEMIOLOGY: DRY-EYE DISEASE, THROUGH 2014</i> .....	71
<i>TABLE 45 FORECAST U.S. EPIDEMIOLOGY: DIABETIC RETINOPATHY, THROUGH 2014</i> .....	71
WESTERN EUROPE.....	71
<i>TABLE 46 FORECAST EPIDEMIOLOGY: WET AMD IN WESTERN EUROPE, THROUGH 2014</i> .....	72
<i>TABLE 47 FORECAST EPIDEMIOLOGY: DRY AMD IN WESTERN EUROPE, THROUGH 2014</i> .....	72
<i>TABLE 48 FORECAST EPIDEMIOLOGY: GLAUCOMA IN WESTERN EUROPE, THROUGH 2014</i> .....	73
<i>TABLE 49 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN WESTERN EUROPE, THROUGH 2014</i> .....	73
<i>TABLE 50 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN WESTERN EUROPE, THROUGH 2014</i> .....	73
JAPAN.....	73

<i>TABLE 51 FORECAST EPIDEMIOLOGY: WET AMD IN JAPAN, THROUGH 2014.....</i>	<i>74</i>
<i>TABLE 52 FORECAST EPIDEMIOLOGY: DRY AMD IN JAPAN, THROUGH 2014.....</i>	<i>74</i>
<i>TABLE 53 FORECAST EPIDEMIOLOGY: GLAUCOMA IN JAPAN, THROUGH 2014.....</i>	<i>75</i>
<i>TABLE 54 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN JAPAN, THROUGH 2014.....</i>	<i>75</i>
<i>TABLE 55 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, THROUGH 2014.....</i>	<i>75</i>
STRATEGIES TO ACCESS EMERGING MARKETS .....	75
STRATEGIES TO ACCESS EMERGING ... (CONTINUED).....	76
EMERGING MARKETS FORECAST.....	77
BRAZIL.....	77
MARKET OVERVIEW .....	77
REGULATORY CONSIDERATIONS .....	78
PATENT CONSIDERATIONS .....	78
<i>TABLE 56 FORECAST EPIDEMIOLOGY: WET AMD IN BRAZIL, THROUGH 2014.....</i>	<i>78</i>
<i>TABLE 57 FORECAST EPIDEMIOLOGY: DRY AMD IN BRAZIL, THROUGH 2014.....</i>	<i>79</i>
<i>TABLE 58 FORECAST EPIDEMIOLOGY: GLAUCOMA, THROUGH 2014 .....</i>	<i>79</i>
<i>TABLE 59 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN BRAZIL, THROUGH 2014.....</i>	<i>79</i>
<i>TABLE 60 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN BRAZIL, THROUGH 2014.....</i>	<i>80</i>
CHINA.....	80
MARKET OVERVIEW .....	80
REGULATORY CONSIDERATIONS .....	80
PATENT CONSIDERATIONS .....	81
<i>TABLE 61 FORECAST EPIDEMIOLOGY: WET AMD IN CHINA, THROUGH 2014.....</i>	<i>82</i>
<i>TABLE 62 FORECAST EPIDEMIOLOGY: DRY AMD IN CHINA, THROUGH 2014.....</i>	<i>82</i>
<i>TABLE 63 FORECAST EPIDEMIOLOGY: GLAUCOMA IN CHINA, THROUGH 2014.....</i>	<i>82</i>
<i>TABLE 64 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN CHINA, THROUGH 2014.....</i>	<i>83</i>
<i>TABLE 65 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN CHINA, THROUGH 2014.....</i>	<i>83</i>
INDIA .....	83
MARKET OVERVIEW .....	83
REGULATORY CONSIDERATIONS .....	84

PATENT CONSIDERATIONS .....	84
TABLE 66 FORECAST EPIDEMIOLOGY: WET AMD IN INDIA, THROUGH 2014.....	85
TABLE 67 FORECAST EPIDEMIOLOGY: DRY AMD IN INDIA, THROUGH 2014.....	85
TABLE 68 FORECAST EPIDEMIOLOGY: GLAUCOMA IN INDIA, THROUGH 2014.....	85
TABLE 69 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN INDIA, THROUGH 2014.....	86
TABLE 70 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN INDIA, THROUGH 2014.....	86
RUSSIA .....	86
MARKET OVERVIEW .....	86
REGULATORY CONSIDERATIONS .....	87
PATENT CONSIDERATIONS .....	87
TABLE 71 FORECAST EPIDEMIOLOGY: WET AMD IN RUSSIA, THROUGH 2014.....	87
TABLE 72 FORECAST EPIDEMIOLOGY: DRY AMD IN RUSSIA, THROUGH 2014.....	88
TABLE 73 FORECAST EPIDEMIOLOGY: GLAUCOMA IN RUSSIA. THROUGH 2014.....	88
TABLE 74 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN RUSSIA, THROUGH 2014.....	88
TABLE 75 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN RUSSIA, THROUGH 2014 .....	89
REGIONAL PREVALENCE FORECASTS .....	89
CENTRAL AMERICA .....	89
Mexico, Belize, Nicaragua, Guatemala.....	89
TABLE 76 FORECAST EPIDEMIOLOGY: WET AMD IN CENTRAL AMERICA, THROUGH 2014 .....	89
TABLE 77 FORECAST EPIDEMIOLOGY: DRY AMD IN CENTRAL AMERICA, THROUGH 2014 .....	89
TABLE 78 FORECAST EPIDEMIOLOGY: GLAUCOMA IN CENTRAL AMERICA, THROUGH 2014 .....	90
TABLE 79 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN CENTRAL AMERICA, THROUGH 2014 .....	90
TABLE 80 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN CENTRAL AMERICA. THROUGH 2014.....	90
SOUTH AMERICA.....	91
Panama, Uruguay, Costa Rica, El Salvador, Honduras, Ecuador, Argentina, Paraguay, Chile, Venezuela, Peru, Bolivia, Colombia .....	91
TABLE 81 FORECAST EPIDEMIOLOGY: WET AMD IN SOUTH AMERICA, THROUGH 2014 .....	91

<i>TABLE 82 FORECAST EPIDEMIOLOGY: DRY AMD IN SOUTH AMERICA, THROUGH 2014</i> .....	91
<i>TABLE 83 FORECAST EPIDEMIOLOGY: GLAUCOMA IN SOUTH AMERICA, THROUGH 2014</i> .....	91
<i>TABLE 84 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN SOUTH AMERICA, THROUGH 2014</i> .....	92
<i>TABLE 85 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN SOUTH AMERICA, THROUGH 2014</i> .....	92
CARRIBEAN .....	92
Jamaica, Dominican Republic, Cuba, Trinidad and Tobago, Haiti, and 10 other Countries Comprising less than 20% of the Region’s Population.....	92
<i>TABLE 86 FORECAST EPIDEMIOLOGY: WET AMD IN THE CARRIBEAN, THROUGH 2014</i> .....	92
<i>TABLE 87 FORECAST EPIDEMIOLOGY: DRY AMD IN THE CARRIBEAN, THROUGH 2014</i> .....	93
<i>TABLE 88 FORECAST EPIDEMIOLOGY: GLAUCOMA IN THE CARRIBEAN, THROUGH 2014</i> .....	93
<i>TABLE 89 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN THE CARRIBEAN THROUGH 2014</i> .....	93
<i>TABLE 90 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN THE CARRIBEAN, THROUGH 2014</i> .....	94
NORTHERN EUROPE .....	94
Norway, Iceland, Finland, Denmark, Sweden .....	94
<i>TABLE 91 FORECAST EPIDEMIOLOGY: WET AMD, NORTHERN EUROPE, THROUGH 2014</i> .....	94
<i>TABLE 92 FORECAST EPIDEMIOLOGY: DRY AMD, NORTHERN EUROPE, THROUGH 2014</i> .....	94
<i>TABLE 93 FORECAST EPIDEMIOLOGY: GLAUCOMA, NORTHERN EUROPE, THROUGH 2014</i> .....	95
<i>TABLE 94 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, NORTHERN EUROPE, THROUGH 2014</i> .....	95
<i>TABLE 95 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, NORTHERN EUROPE, THROUGH 2014</i> .....	95
CENTRAL AND EASTERN EUROPE.....	96
Serbia, Liechtenstein, Estonia, Slovenia, Macedonia, Latvia, Albania, Lithuania, Bosnia and Herzegovina, Croatia, Georgia, Slovakia, Azerbaijan, Bulgaria, Belarus, Hungary, Czech Republic, Romania, Poland, Ukraine, Netherlands Antilles, Montenegro, Cyprus, Armenia, Turkmenistan .....	96
<i>TABLE 96 FORECAST EPIDEMIOLOGY: WET AMD, CENTRAL AND EASTERN EUROPE, THROUGH 2014</i> .....	96



<i>TABLE 97 FORECAST EPIDEMIOLOGY: DRY AMD, CENTRAL AND EASTERN EUROPE, THROUGH 2014</i> .....	96
<i>TABLE 98 FORECAST EPIDEMIOLOGY: GLAUCOMA, CENTRAL AND EASTERN EUROPE, THROUGH 2014</i> .....	96
<i>TABLE 99 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, CENTRAL AND EASTERN EUROPE, THROUGH 2014</i> .....	97
<i>TABLE 100 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, CENTRAL AND EASTERN EUROPE, THROUGH 2014</i> .....	97
AUSTRALIA.....	97
Australia, Guinea, New Zealand, Papua New Guinea, Pipeline Analysis.....	97
<i>TABLE 101 FORECAST EPIDEMIOLOGY: WET AMD IN AUSTRALIA</i> .....	97
<i>TABLE 102 FORECAST EPIDEMIOLOGY: DRY AMD IN AUSTRALIA, THROUGH 2014</i> .....	98
<i>TABLE 103 FORECAST EPIDEMIOLOGY: GLAUCOMA IN AUSTRALIA, THROUGH 2014</i> .....	98
<i>TABLE 104 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN AUSTRALIA, THROUGH 2014</i> .....	98
<i>TABLE 105 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN AUSTRALIA, THROUGH 2014</i> .....	99
ASIA-OTHER.....	99
Indonesia, Pakistan, Bangladesh, Philippines, Vietnam, Turkey, Thailand, South Korea, Burma, Nepal, Afghanistan, Uzbekistan, and 76 Other Countries Comprising 18% of the Region’s Population.....	99
<i>TABLE 106 FORECAST EPIDEMIOLOGY: WET AMD, ASIA-OTHER, THROUGH 2014</i> .....	99
<i>TABLE 107 FORECAST EPIDEMIOLOGY: DRY AMD, ASIA-OTHER, THROUGH 2014</i> .....	99
<i>TABLE 108 FORECAST EPIDEMIOLOGY: GLAUCOMA, ASIA-OTHER, THROUGH 2014</i> .....	100
<i>TABLE 109 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, ASIA-OTHER, THROUGH 2014</i> .....	100
<i>TABLE 110 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, ASIA-OTHER, THROUGH 2014</i> .....	100
MIDDLE EAST.....	101
United Arab Emirates, Saudi Arabia, Israel, Gaza Strip, Kuwait, West Bank, Lebanon, Jordan, Syria, Yemen, Iraq, Iran.....	101
<i>TABLE 111 FORECAST EPIDEMIOLOGY: WET AMD, MIDDLE EAST, THROUGH 2014</i> .....	101
<i>TABLE 112 FORECAST EPIDEMIOLOGY: DRY AMD, MIDDLE EAST, THROUGH 2014</i> .....	101

<i>TABLE 113 FORECAST EPIDEMIOLOGY: GLAUCOMA, MIDDLE EAST, THROUGH 2014</i> .....	101
<i>TABLE 114 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, MIDDLE EAST, THROUGH 2014</i> .....	102
<i>TABLE 115 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, MIDDLE EAST, THROUGH 2014</i> .....	102
SOUTHERN AFRICA .....	102
South Africa, Cape Verde, Malawi, Swaziland, Botswana, Zambia, Angola, Zimbabwe.....	102
<i>TABLE 116 FORECAST EPIDEMIOLOGY: WET AMD, SOUTHERN AFRICA, THROUGH 2014</i> .....	102
<i>TABLE 117 FORECAST EPIDEMIOLOGY: DRY AMD, SOUTHERN AFRICA, THROUGH 2014</i> .....	103
<i>TABLE 118 FORECAST EPIDEMIOLOGY: GLAUCOMA, SOUTHERN AFRICA, THROUGH 2014</i> .....	103
<i>TABLE 119 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, SOUTHERN AFRICA THROUGH 2014</i> .....	103
<i>TABLE 120 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, SOUTHERN AFRICA, THROUGH 2014</i> .....	104
AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST .....	104
CHAPTER SEVEN: PIPELINE ANALYSIS .....	105
<i>TABLE 121 APPROVED PRODUCT SALES FORECAST, 2008-2014 (\$ MILLIONS)</i> .....	105
<i>TABLE 122 PIPELINE SALES FORECAST, 2008-2014 (\$ MILLIONS)</i> .....	105
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT .....	106
STRINGENT REGULATORY PATHWAY EXISTS FOR DRY-EYE DISEASE .....	106
Sustained Delivery Is a Common Trait Among Leading Products in Development.....	106
Sustained Delivery ...(Continued) .....	107
SiRNA Therapies in Development Experience Systemic Safety Concerns.....	108
2009 APPROVALS IN OPHTHALMOLOGY THERAPY.....	109
ACUVAIL.....	109
<i>TABLE 123 SNAPSHOT OF ACUVAIL</i> .....	110
Clinical Results.....	110
BEPREVE.....	110
<i>TABLE 124 SNAPSHOT OF BEPREVE</i> .....	111
Clinical Results.....	111
BESIVANCE.....	111
<i>TABLE 125 SNAPSHOT OF BESIVANCE</i> .....	112
OZURDEX .....	113
<i>TABLE 126 SNAPSHOT OF OZURDEX</i> .....	113

ZIRGAN .....	114
OPHTHALMIC DRUGS IN ADVANCED DEVELOPMENT .....	115
PHASE III.....	115
VEGF Trap-Eye .....	115
<i>TABLE 127 SNAPSHOT OF VEGF TRAP-EYE</i> .....	<i>116</i>
Clinical Results .....	116
Iluvien .....	117
<i>TABLE 128 SNAPSHOT OF ILUVIEN</i> .....	<i>117</i>
Clinical Results .....	117
Luveniq .....	118
<i>TABLE 129 SNAPSHOT OF LUVENIQ</i> .....	<i>118</i>
PHASE II .....	119
Ecabet.....	119
<i>TABLE 130 SNAPSHOT OF ECABET</i> .....	<i>119</i>
Clinical Results .....	119
Androgen Tears .....	120
<i>TABLE 131 SNAPSHOT OF ANDROGEN TEARS</i> .....	<i>120</i>
PIPELINE ANALYSIS BY COMPANY .....	121
<i>TABLE 132 ALCON'S OPTHALMIC PIPELINE</i> .....	<i>121</i>
<i>TABLE 133 ALLERGAN'S OPTHALMIC PIPELINE</i> .....	<i>121</i>
<i>TABLE 134 PFIZER'S OPTHALMIC PIPELINE</i> .....	<i>121</i>
<i>TABLE 135 NOVARTIS' OPTHALMIC PIPELINE</i> .....	<i>122</i>
<i>TABLE 136 NOVARTIS' OPTHALMIC PIPELINE</i> .....	<i>122</i>
<i>TABLE 137 MERCK OPTHALMIC PIPELINE</i> .....	<i>122</i>
<i>TABLE 138 SANTEN OPTHALMIC PIPELINE</i> .....	<i>123</i>
CHAPTER EIGHT: COMPANY PROFILES .....	124
SUMMARY.....	124
ABBOT MEDICAL PRODUCTS .....	125
Business Overview .....	125
Leading Products .....	125
Corporate Strategy .....	125
ACUCELA .....	125
Business Overview .....	125
Leading Products .....	126
Corporate Strategy .....	126
AERIE PHARMA .....	126
Business Overview .....	127
Leading Products .....	127
Corporate Strategy .....	127
AKORN, INC. ....	127
Business Overview .....	128
Leading Products .....	128
Akten .....	128
Timolol Maleate .....	128

Corporate Strategy .....	128
ALCON .....	129
Business Overview .....	129
Leading Products .....	129
Pataday.....	130
Vigamox.....	130
Nevanac.....	130
Triesence .....	130
Tobradex.....	130
Travatan and Travatan Z.....	130
Azopt.....	131
Azarga .....	131
Duotrav.....	131
Corporate Strategy .....	131
ALIMERA SCIENCES .....	131
Business Overview .....	132
Leading Products .....	132
Iluvien .....	132
Other Products.....	132
Corporate Strategy .....	132
ALLERGAN, INC. ....	133
Business Overview .....	133
Leading Products .....	133
Restasis and Others.....	133
Lumigan and Others.....	133
Corporate Strategy .....	134
CAN-FITE BIOPHARMA LTD. ....	134
Business Overview .....	135
Leading Products .....	135
Corporate Strategy .....	135
COMENTIS .....	135
Business Overview .....	136
Leading Products .....	136
ATG-3 .....	136
Corporate Strategy .....	136
DANUBE PHARMACEUTICALS .....	136
Business Overview .....	137
Leading Products .....	137
DNB-001 .....	137
Corporate Strategy .....	137
ESBATECH .....	137
Business Overview .....	137
Leading Products .....	138
ESBA105 .....	138

Corporate Strategy .....	138
EYEGATE PHARMA .....	138
Business Overview .....	138
Leading Products .....	138
EGP-437 .....	138
Corporate Strategy .....	139
GENENTECH .....	139
Business Overview .....	139
Leading Products .....	139
Lucentis .....	139
Avastin (Bevacizumab) .....	140
Corporate Strategy .....	140
GENE SIGNAL .....	141
Business Overview .....	141
Leading Products .....	141
GS-101 .....	141
Corporate Strategy .....	141
ICO THERAPEUTICS .....	142
Business Overview .....	142
Leading Products .....	142
Corporate Strategy .....	142
INSITE VISION .....	143
Business Overview .....	143
Leading Products .....	143
AzaSite .....	143
Corporate Strategy .....	143
INSPIRE PHARMACEUTICALS, INC .....	143
Business Overview .....	144
Leading Products .....	144
Prolactria (diquafosol tetrasodium) .....	144
Additional Products .....	144
Corporate Strategy .....	145
IRIDEX .....	145
Business Overview .....	145
Leading Products .....	145
Transpupillary Thermotherapy .....	145
Corporate Strategy .....	146
ISTA PHARMACEUTICALS .....	146
Business Overview .....	146
Leading Products .....	146
Bepreve .....	146
Xibrom .....	147
Istalol .....	147
Corporate Strategy .....	147

JERINI AG .....	147
Business Overview .....	147
Leading Products .....	148
$\alpha 5\beta 1$ Integrin (JSM 6427) .....	148
Corporate Strategy .....	148
LPATH INCORPORATED .....	148
Business Overview .....	148
Leading Products .....	148
ISONEP .....	148
Corporate Strategy .....	149
LUX BIOSCIENCES .....	149
Business Overview .....	149
Leading Products .....	149
Luveniq .....	149
Corporate Strategy .....	150
MACUSIGHT .....	150
Website: <a href="http://www.macusight.com/">www.macusight.com/</a> .....	150
Business Overview .....	150
Leading Products .....	151
Perceiva .....	151
Corporate Strategy .....	151
MERCK .....	151
Business Overview .....	151
Corporate Strategy .....	152
NEUROTECH .....	152
Business Overview .....	152
Leading Products .....	153
Company Strategy .....	153
NICOX S.A. ....	153
Business Overview .....	153
Leading Products .....	154
NCX 116 .....	154
Corporate Strategy .....	154
NOVARTIS .....	154
Business Overview .....	154
Leading Products .....	155
Lucentis .....	155
Visudyne .....	155
Company Strategy .....	155
OPKO HEALTH .....	155
Business Overview .....	155
Leading Products .....	156
Bevasiranib .....	156
Civamide .....	156

Doxovir .....	156
Company Strategy .....	157
OSI PHARMACEUTICALS .....	157
Business Overview .....	157
Leading Products .....	157
Macugen .....	157
Corporate Strategy .....	158
OTHERA.....	158
Business Overview .....	158
Leading Products .....	158
Corporate Strategy .....	159
Business Overview .....	159
Leading Products .....	159
Zybrestat .....	159
Corporate Strategy .....	159
PFIZER.....	160
Business Overview .....	160
Leading Products .....	160
Xalatan (latanoprost. ophthalmic solution) .....	160
Corporate Strategy .....	160
POTENTIA PHARMACEUTICALS .....	161
Business Overview .....	161
Leading Products .....	161
POT-4.....	161
Corporate Strategy .....	161
QLT INC. ....	161
Business Overview .....	162
Leading Products .....	162
Visudyne.....	162
Corporate Strategy .....	162
PSIVIDA CORPORATION .....	163
Business Overview .....	163
Leading Products .....	163
Iluvien .....	163
Retisert.....	163
Corporate Strategy .....	163
QUARK BIOTECH.....	164
Business Overview .....	164
Leading Products .....	164
PF-4523655 .....	164
Corporate Strategy .....	164
REGENERON .....	165
Business Overview .....	165
Leading Products .....	165

VEGF-Trap Eye .....	165
Corporate Strategy .....	165
SANOFI-AVENTIS .....	166
Business Overview .....	166
Leading Products .....	166
Prednisporin.....	166
FOV2302.....	166
Corporate Strategy .....	167
SANTEN SEIYAKU .....	167
Business Overview .....	167
Leading Products .....	168
Hyalein .....	168
Cravit/Oftaquix .....	168
Corporate Strategy .....	168
SANWA KAGAKU KENKYUSHO CO., LTD .....	168
Business Overview .....	168
Leading Products .....	168
Corporate Strategy .....	169
SIRION THERAPEUTICS.....	169
Business Overview .....	169
Leading Products .....	169
Durezol .....	169
Zirgan .....	169
Corporate Strategy .....	170
TARGEGEN .....	170
Business Overview .....	170
Leading Products .....	170
TG100801 .....	170
THROMBOGENICS.....	171
Business Overview .....	171
Leading Products .....	171
Microplasmin .....	171
Corporate Strategy .....	171
VITREORETINAL TECHNOLOGIES .....	172
Business Overview .....	172
Leading Products .....	172
Vitreosolve.....	172
Corporate Strategy .....	172
LEADING UNITED STATES EYE RESEARCH CENTERS .....	172
MASSACHUSETTS EYE & EAR INFIRMARY .....	172
Summary.....	173
BASCOM PALMER EYE INSTITUTE .....	173
Summary.....	173
DOHENY EYE INSTITUTE.....	173



Summary.....	173
JULES STEIN EYE INSTITUTE.....	173
Summary.....	174
THE CULLEN EYE INSTITUTE – BAYLOR COLLEGE OF MEDICINE.....	174
Summary.....	174
THE WILMER EYE INSTITUTE AT JOHNS HOPKINS HOSPITAL.....	174
Summary.....	174
WILLS EYE HOSPITAL.....	174
Summary.....	174
CLAY COUNTY HOSPITAL.....	175
Summary.....	175
FORT LAUDERDALE EYE INSTITUTE.....	175
Summary.....	175
PHILLIPS EYE INSTITUTE.....	175
Summary.....	175
SELECTED GLOBAL EYE HOSPITALS.....	176
INDIA.....	176
Aravind Eye Hospital in India.....	176
Summary.....	176
Al-Shifa Hospital.....	176
Summary.....	176
CHINA.....	176
He Eye Hospital.....	176
Summary.....	177